Dystonia Musculorum Deformans
- 1 June 1982
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 39 (6) , 376-377
- https://doi.org/10.1001/archneur.1982.00510180054014
Abstract
• Sporadic, autosomal recessive and dominant forms of dystonia musculorum deformans have been recognized. This communication reports the results of treatment of six patients with this condition. Two patients with the recessive form responded to levodopa therapy. Three patients who responded to carbamazepine therapy probably have the dominant form. In one patient, response to carbamazepine therapy was equivocal. It is suggested that such therapeutic responsiveness may reflect underlying biochemical differences in the recessive and dominant forms of the disease.This publication has 8 references indexed in Scilit:
- The Newer Antiepileptic Drugs: Carbamazepine and Valproic AcidPediatric Annals, 1991
- Effect of carbamazepine on cholinergic parameters in rat brain areasNeuropharmacology, 1976
- Dystonic symptoms in children. Treatment with carbamazepinePublished by American Medical Association (AMA) ,1974
- Biochemical and pharmacologic studies of dystoniaNeurology, 1970
- Preliminary remarks on the L‐dopa therapy of dystoniaNeurology, 1970
- Torsion dystonia and spasmodic torticollis—results of treatment with L‐dopaNeurology, 1970
- The treatment of dystonia with L‐dopa and haloperidolNeurology, 1970
- The torsion dystoniasNeurology, 1970